{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:10:22Z","timestamp":1787159422590,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40265-024-02133-1","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T03:19:15Z","timestamp":1737083955000},"page":"255-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Liposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic Adenocarcinoma"],"prefix":"10.1007","volume":"85","author":[{"given":"Michael B.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"issue":"3","key":"2133_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"2133_CR2","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.3390\/curroncol30110694","volume":"30","author":"I Garajov\u00e1","year":"2023","unstructured":"Garajov\u00e1 I, Peroni M, Gelsomino F, et al. A simple overview of pancreatic cancer treatment for clinical oncologists. Curr Oncol. 2023;30(11):9587\u2013601.","journal-title":"Curr Oncol"},{"issue":"7","key":"2133_CR3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40265-020-01304-0","volume":"80","author":"RR Singh","year":"2020","unstructured":"Singh RR, O\u2019Reilly EM. New treatment strategies for metastatic pancreatic ductal adenocarcinoma. Drugs. 2020;80(7):647\u201369.","journal-title":"Drugs"},{"key":"2133_CR4","unstructured":"National Cancer Institute. SEER cancer stat facts: pancreatic cancer. 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html. Accessed 21 Nov 2024."},{"issue":"7","key":"2133_CR5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40265-017-0741-1","volume":"77","author":"YN Lamb","year":"2017","unstructured":"Lamb YN, Scott LJ. Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs. 2017;77(7):785\u201392.","journal-title":"Drugs"},{"issue":"6","key":"2133_CR6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00280-008-0839-y","volume":"63","author":"SY Yi","year":"2009","unstructured":"Yi SY, Park YS, Kim HS, et al. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol. 2009;63(6):1141\u20135.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2133_CR7","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/IJN.S88084","volume":"11","author":"AH Ko","year":"2016","unstructured":"Ko AH. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. Int J Nanomedicine. 2016;11:1225\u201335.","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"2133_CR8","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","volume":"66","author":"DC Drummond","year":"2006","unstructured":"Drummond DC, Noble CO, Guo Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66(6):3271\u20137.","journal-title":"Cancer Res"},{"issue":"10","key":"2133_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s40265-020-01336-6","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Liposomal Irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs. 2020;80(10):1007\u201318.","journal-title":"Drugs"},{"key":"2133_CR10","unstructured":"Ipsen Biopharmaceuticals Inc. ONIVYDE\u00ae (irinotecan liposome injection), for intravenous use: US prescribing information. 2024. https:\/\/www.fda.gov\/. Accessed 21 Nov 2024."},{"key":"2133_CR11","unstructured":"European Medicines Agency. Onivyde pegylated liposomal: EU summary of product characteristics. 2024. https:\/\/www.ema.europa.eu. Accessed 21 Nov 2024."},{"issue":"10","key":"2133_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","volume":"57","author":"FM de Man","year":"2018","unstructured":"de Man FM, Goey AKL, van Schaik RHN, et al. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229\u201354.","journal-title":"Clin Pharmacokinet"},{"issue":"23","key":"2133_CR13","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","volume":"74","author":"AV Kalra","year":"2014","unstructured":"Kalra AV, Kim J, Klinz SG, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014;74(23):7003\u201313.","journal-title":"Cancer Res"},{"issue":"12","key":"2133_CR14","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/psp4.12725","volume":"10","author":"K Brendel","year":"2021","unstructured":"Brendel K, Bekaii-Saab T, Boland PM, et al. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. CPT Pharmacometrics Syst Pharmacol. 2021;10(12):1550\u201363.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10409","key":"2133_CR15","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX vs nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272\u201381.","journal-title":"Lancet"},{"key":"2133_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2021.03.028","volume":"151","author":"ZA Wainberg","year":"2021","unstructured":"Wainberg ZA, Bekaii-Saab T, Boland PM, et al. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: a phase I\/II study. Eur J Cancer. 2021;151:14\u201324.","journal-title":"Eur J Cancer"},{"issue":"16 Suppl","key":"2133_CR17","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1200\/JCO.2024.42.16_suppl.4136","volume":"42","author":"MA Hussein","year":"2024","unstructured":"Hussein MA, Khan G, Chandana SR, et al. NALIRIFOX vs nab-paclitaxel and gemcitabine in treatment-na\u00efve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): updated overall survival analysis with 29-month follow-up of NAPOLI 3. J Clin Oncol. 2024;42(16 Suppl):4136.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2133_CR18","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.annonc.2024.05.466","volume":"35","author":"T Macarulla Mercade","year":"2024","unstructured":"Macarulla Mercade T, Pazo Cid RA, Womack M, et al. NALIRIFOX vs nab-paclitaxel and gemcitabine (Gem+NabP) in treatment-na\u00efve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): subgroup analysis of patients aged 65 years or older in NAPOLI 3 [abstract no. 323P plus poster]. Ann Oncol. 2024;35(Suppl 1):S135\u20136.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"2133_CR19","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1016\/j.annonc.2024.05.467","volume":"35","author":"W Lee","year":"2024","unstructured":"Lee W, Kim IH, Oh SC, et al. Effect of NALIRIFOX in Asian patients (pts) with treatment-naive metastatic pancreatic adenocarcinoma (mPAC): results from the NAPOLI 3 trial [abstract no. 324P plus poster]. Ann Oncol. 2024;35(Suppl 1):S136\u20137.","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"2133_CR20","doi-asserted-by":"publisher","first-page":"S896","DOI":"10.1016\/j.annonc.2023.09.2568","volume":"34","author":"D Melisi","year":"2023","unstructured":"Melisi D, Macarulla T, de la Fouchardiere C, et al. Health-related quality of life with NALIRIFOX vs nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): EORTC QLQ-C30 results from the NAPOLI 3 trial. Ann Oncol. 2023;34(Suppl 2):S896\u20137.","journal-title":"Ann Oncol"},{"issue":"10409","key":"2133_CR21","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/S0140-6736(23)01521-0","volume":"402","author":"MG Besselink","year":"2023","unstructured":"Besselink MG, Wilmink JW. Treating metastatic pancreatic ductal adenocarcinoma: NALIRIFOX as new standard? Lancet. 2023;402(10409):1217\u20138.","journal-title":"Lancet"},{"issue":"2","key":"2133_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.21037\/hbsn-24-37","volume":"13","author":"C Springfeld","year":"2024","unstructured":"Springfeld C, Bailey P, Buchler MW, et al. ESMO 2023 pancreatic cancer guidelines signal stepwise progress. Hepatobiliary Surg Nutr. 2024;13(2):362\u20135.","journal-title":"Hepatobiliary Surg Nutr."},{"issue":"1","key":"2133_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/OP.22.00328","volume":"19","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Sohal DPS. Pancreatic adenocarcinoma management. JCO Oncol Pract. 2023;19(1):19\u201332.","journal-title":"JCO Oncol Pract."},{"key":"2133_CR24","unstructured":"National Comprehensive Cancer Network. NCCN pancreatic adenocarcinoma guidelines v2-2024. https:\/\/www.nccn.org. Accessed 21 Nov 2024."},{"issue":"4","key":"2133_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/cancers11040484","volume":"11","author":"S Pusceddu","year":"2019","unstructured":"Pusceddu S, Ghidini M, Torchio M, et al. Comparative effectiveness of gemcitabine plus nab-paclitaxel and NALIRIFOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis. Cancers (Basel). 2019;11(4):484. https:\/\/pubmed.ncbi.nlm.nih.gov\/30959763\/","journal-title":"Cancers (Basel)."},{"issue":"4 Suppl","key":"2133_CR26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2020.38.4_suppl.666","volume":"38","author":"EM O'Reilly","year":"2020","unstructured":"O\u2019Reilly EM, Surinach A, Wu Z, et al. Real-world patterns of care among patients with metastatic pancreatic cancer (mPC) [abstract no. 666]. J Clin Oncol. 2020;38(4 Suppl):666.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2133_CR27","doi-asserted-by":"publisher","first-page":"8934","DOI":"10.1002\/cam4.4415","volume":"10","author":"KH Yu","year":"2021","unstructured":"Yu KH, Ozer M, Cockrum P, et al. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Cancer Med. 2021;10(24):8934\u201343.","journal-title":"Cancer Med"},{"issue":"1","key":"2133_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2023.50756","volume":"7","author":"F Nichetti","year":"2024","unstructured":"Nichetti F, Rota S, Ambrosini P, et al. NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(1):1\u201313.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2133_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.currproblcancer.2018.01.013","volume":"42","author":"AR Lewis","year":"2018","unstructured":"Lewis AR, Pihlak R, McNamara MG. The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. Curr Probl Cancer. 2018;42(1):26\u201339.","journal-title":"Curr Probl Cancer"},{"issue":"19","key":"2133_CR30","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX vs gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"8","key":"2133_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41571-024-00896-w","volume":"21","author":"C Nevala-Plagemann","year":"2024","unstructured":"Nevala-Plagemann C, Garrido-Laguna I. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nat Rev Clin Oncol. 2024;21(8):567\u20138.","journal-title":"Nat Rev Clin Oncol"},{"issue":"16 Suppl","key":"2133_CR32","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1200\/JCO.2024.42.16_suppl.4160","volume":"42","author":"X Jiao","year":"2024","unstructured":"Jiao X, Barzi A. Comparative effectiveness of NALIRIFOX vs. FOLFIRINOX in pancreatic cancer. [abstract no. 4160]. J Clin Oncol. 2024;42(16 Suppl):4160.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2133_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12962-024-00578-5","volume":"22","author":"H Shao","year":"2024","unstructured":"Shao H, Fang H, Li Y, et al. Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective. Cost Eff Resour Alloc. 2024;22(1):70.","journal-title":"Cost Eff Resour Alloc."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02133-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:26:48Z","timestamp":1766564808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02133-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2133"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02133-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"21 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to a retrospective open access request funded by Ipsen Biopharmaceuticals Inc, and Servier.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Michael B. Brown and Hannah A. Blair are salaried employees of Adis International Ltd\/Springer Nature and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}